Lupin500257Pharmaceuticals
Lupin received USFDA approval for a muscle weakness drug
By ScoutQuest · · 1 min read
Heard on business television between 07:46:31 - 07:49:31 IST.
- Lupin saw positive news flow after receiving USFDA approval for a drug treating muscle weakness.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Lupin
Lupin Q2 FY27 investor presentation: sales up 14.0% YoY, EBITDA margin down to 25.1%
4 Nov 2026
Lupin Q2 FY2027: EBITDA falls 10.7% YoY to INR 21,712 Mn, EBITDA margin narrows 770 bps to 27.9%
4 Nov 2026
Q2/H1 FY27 results approved; consolidated net profit ₹11,553.0 million, standalone loss ₹59.1 million
4 Nov 2026
Source: Live TV News Channel · 3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.